Fritextsökning
Innehållstyper
-
Life science trends 2025 – The economy
Upcoming patent expirations are driving pharmaceutical companies to acquire in 2025. In Sweden, we may be on our way to brighter times and fewer bankruptcies. T...
-
Bioscience – Groundbreaking Research & Diagnostics: Stockholm
-
ZEISS continues to drive digital era forward in ophthalmology
2 million digitally planned cataract cases in the U.S. alone.
-
Webinar: Support Trial Patients Transitioning to the Commercial Space
Register for expert insights on supporting Phase III clinical trial patients post-approval and read our blog on advanced Patient Assistance Programs.
-
Novo Nordisk cuts ties with Hims & Hers after Wegovy dispute
Novo Nordisk is ending its collaboration with Hims & Hers Health due to concerns about the company’s sales and marketing practices related to the weight-loss drug Wegovy.
-
High-tech companies are increasingly focusing on health
Tech companies have been taking an interest in healthcare for many years, and this interest seems to be increasing. “It’s not a sudden shift in trend, it’s more...
-
The dock that “thinks” for itself
The world of bulk material handling seems straightforward at first glance: moving, filling, delivering. However, the art of dealing with a variety of different ...
-
Vaccine skeptic David Geier to lead study on link to autism
The American government is to launch a study on whether vaccines cause autism – and has appointed a well-known vaccine skeptic to lead the analysis.
-
Major investment in women’s health – for a more equal healthcare system
”The regional differences need to decrease and the long-term supply of midwives and other professions needs to be secured,” write Acko Ankarberg Johansson and D...
-
It couldn’t be simpler
AI-assisted ZEISS Solution inspects implant coatings automatically.
-
Life science trends 2025 – Part 1 obesity drugs
More obesity drugs are being launched this year following Novo Nordisk and Eli Lilly's previous successes with GLP-1 drugs. But the next big breakthrough in obe...
-
Try arivis for free
30-day free trial offers a number of benefits.
-
Non-destructive testing and assembly control
Assess complete assembly.
-
New features in ZEISS CALYPSO 2024
ZEISS CALYPSO is your universal software for dimensional metrology applications.
-
MSD discontinues development of cancer drugs after trial failures
MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.
-
Cellevate stärker ledningen – utnämner CTO
Biotechbolaget Cellevate utnämner Christel Fenge till Chief Technology Officer (CTO).
-
Tio life science-projekt får miljonanslag – ny utlysning öppnar
En rad life science-projekt har fått miljonanslag i ett svenskt proof of concept-program. 13 januari öppnar en ny utlysning.
-
Kennedy stoppar bidrag till vaccinalliansen Gavi
USA kommer inte längre ge ekonomiskt stöd till Gavi förrän den globala vaccinalliansen ”återvunnit allmänhetens förtroende”. Det meddelar USA:s hälsominister Ro...
-
Tryckreglering med global expertis – OEM Automatic erbjuder lösningar från Tescom
OEM Automatic tillhandahåller tryckregulatorer och ventiler från Tescom – en erkänd aktör med över ett sekel av erfarenhet inom precisionsstyrning av gaser och ...
-
FDA’s Top Vaccine Official resigns – Issues sharp criticism of Kennedy
FDA’s Top Vaccine Official is leaving his post while simultaneously criticizing the country’s health secretary for allowing “misinformation and lies” to influen...
-
LINK Medical recruits Swedish CEO
The Norwegian Contract Research Organization LINK Medical has recruited Anders Göransson as the new CEO.
-
USA:s regering skrotar vaccinavtal med Moderna
Trumpadministrationen har avbrutit ett kontrakt som tilldelats Moderna för den sena utvecklingsfasen av ett fågelinfluensavaccin för människor, samt rätten att ...
-
Elevating 3D characterization with enhanced performance and efficiencies
Introducing the ZEISS VersaXRM 730 3D X-ray microscope.
-
BioArctic moves forward with its candidate for Parkinson’s
BioArctic announces positive early phase study results for its drug candidate for Parkinson’s disease.